Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07625345 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorEligibility criteria expanded, about 20 words
Study description revised
MinorRe-verified, no change to tracked fieldsv23
MinorStart date changed from estimate of Jul 8, 2026 to Jul 1, 2026v22
MinorStart date: Jul 7, 2026 to Jul 8, 2026v21
Show 19 earlier versionsHide 19 earlier versions
MinorStart date: Jul 6, 2026 to Jul 7, 2026v20
MinorStart date: Jul 5, 2026 to Jul 6, 2026v19
MinorStart date: Jul 2, 2026 to Jul 5, 2026v18
MinorStart date: Jul 1, 2026 to Jul 2, 2026v17
MinorStart date: Jun 30, 2026 to Jul 1, 2026v16
MinorStart date: Jun 29, 2026 to Jun 30, 2026v15
MinorStart date: Jun 28, 2026 to Jun 29, 2026v14
MinorStart date: Jun 24, 2026 to Jun 28, 2026v13
MinorStart date: Jun 23, 2026 to Jun 24, 2026v12
MinorStart date: Jun 22, 2026 to Jun 23, 2026v11
MinorStart date: Jun 21, 2026 to Jun 22, 2026v10
MinorStart date: Jun 18, 2026 to Jun 21, 2026v9
MinorStart date: Jun 17, 2026 to Jun 18, 2026v8
MinorStart date: Jun 16, 2026 to Jun 17, 2026v7
MinorStart date: Jun 15, 2026 to Jun 16, 2026v6
MinorStart date: Jun 14, 2026 to Jun 15, 2026
Eligibility criteria shortened, about 3 words
v5
MinorStart date: Jun 11, 2026 to Jun 14, 2026v4
MinorStart date: Jun 10, 2026 to Jun 11, 2026v3
MinorStart date: Jun 9, 2026 to Jun 10, 2026v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background:
PDE4B is a protein in cells that helps turn off certain chemical signals after they ve done their job. It controls inflammation, immune responses, and some brain signaling. Measuring PDE4B levels in the body can help doctors manage a disease or know if a treatment is working. Researchers want to find out if a new tracer (a radioactive substance injected during imaging scans) can help them measure PDE4B in people more effectively.
Objective:
To test a new tracer (\[11C\]ZTP-1) during imaging scans of the brain and body in healthy people.
Eligibility:
Healthy people aged 18 and older. They must have been screened under protocols 01M-0254 or 17M0181.
Design:
Participants will have either 1 or 2 clinic visits.
During their first visit, all participants will have a positron emission tomography (PET)/computed tomography (CT) scan. Prior to the scan, they will have blood and urine tests and a test of their heart function. The study tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body.
Some participants will have a PET/CT scan of their whole body. They will need only 1 visit. The visit will last up to about 8 hours.
Some participants will have a PET/CT scan of only their brain. They will also have a magnetic resonance imaging (MRI) scan of the brain. They may need to return for a second visit for the MRI scan.
Participants will receive a follow-up call to check on their well-being after their PET/CT scans.